LEE CHENG LIU

PRESIDENT & CEO

Dr. Liu has 30 years of product, process development and manufacturing experience in biotech, pharmaceutical and specialty chemical industries. Prior to returning to Taiwan to start up EirGenix, Dr. Liu was the President and COO of AnGes Inc., a biotech enterprise in its late developmental stage.  

He joined AnGes in 2002 as a Vice President of Product Management. He also served as a Vice Chairman in the Supervisory Board of Avontec GmbH, a Munich based joint venture with AnGes, from 2004 to 2010. 

Before his tenure with AnGes, he had served various management and professional positions to lead product/process development at GenVec, Novartis, W.R.Grace & Co. and Halcon SD.  

Dr Liu holds a doctoral degree in Chemical Engineering & Applied Chemistry from Columbia University, and a BS degree in Chemical Engineering from National Taiwan University.

YOU NAN SHIH

Senior Vice President of Quality System

Dr. Shih Joined EirGenix in June 2015. He has over 25 years of experience in the pharmaceutical and specialty chemical industries. Prior to joining EirGenix, Dr. Shih was the Vice President Quality at ScinoPharm Taiwan, an active pharmaceutical ingredient company and GMP consultant of global clients.

He joined ScinoPharm in 1998 as QA Manager. Before ScinoPharm Taiwan, he served as the Technical Manager of Ciba Specialty Chemicals – Novartis – Ciba-Geigy, specializing in QSHE (quality, safety, health and environment).

Dr. Shih did the post-doctoral study at University of Minnesota, earned his doctoral degree in Chemistry from Cornell University, and BS degree in Chemistry from Tamkang University.

THOMAS SCHULZE

Unit Vice President of Product Development & Operations Unit

Dr. Thomas Schulze`s scope of experience covers numerous areas in pharmaceutical R&D and biotechnology, including biological and small molecule drug discovery and development, molecular diagnostics and product authentication.

From 1990 – 1999, he worked in pharmaceutical drug discovery and development at Bayer AG and Bayer Yakuhin, Ltd. while heading a department in Japan and global drug discovery and genomics projects across several indication areas in Germany. During 1999 – 2012, he served in different executive management positions as COO, CEO and Interim-CEO at several industrial biotech companies, including November AG, Avontec GmbH, Formycon AG.

From 1984 – 1990, he worked at the Max Planck Institute for Molecular Genetics on the characterization of the HIV replication cycle in Berlin where he conducted his diploma and doctoral thesis. Dr. Schulze received his doctoral degree from the Free University Berlin/Dept. Biology in 1989.

CHIH JUNG CHANG

Unit Vice President of Contract Development & Manufacturing Operations Unit

Dr Chih-Jung Chang is an Organic Chemist and has majored on the pharmaceutical field for nearly 20 years. He once worked as the director of TOT Oncology Business Unit at TTY Biopharm. During which, his main responsibilities included project management creating business and drug development strategies for licensing and collaboration in global NCE (Specialty)/Biologics (NBE/Biosimilars) projects. 

With both technical knowledge and business acumen, Dr. Chang has extensive experiences building up new biologics and specialty pipelines that fit the company’s development strategy. In addition, Dr Chang has extensive experiences managing international networking and relationships for value-added bridge between early and late stage drug development. In particular, Dr Chang has extensive experiences working with global CRO/CMO resources to fast track drug development. 

Before assuming the current position, Dr Chang was with TaiGen Biotechnology and was in charge of managing the company’s R&D projects and business development.

FRANK HO

Vice President of Manufacturing Technical Operation & Process Development

Dr. Frank Ho, a Ph.D. graduate from UC Davis, has been working in the biotechnology industry since 1992 after spending 10 years in the academia. 

His industry experience has been in the areas of process development, process transfer, manufacturing, and contract manufacturing at several biotech companies in the San Francisco Bay Area, including Chiron, Fibrogen, Applied Biosystems, Raven, BioMarin and most recently in Asia he worked with PharmaEssentia in Taipei and A-Bio in Singapore. 

He has extensive experience in managing cross-functional, bridging scientific and operational teams to achieve company goals. He has accomplished 10 FDA-approved biologics through process development, and has led and transferred more than 40 biologics for GMP manufacturing internally. Externally, he has led several international contract manufacturing campaigns in Europe, North America and Asia. 

He has held positions in responsible for manufacturing facility/engineering design, start-up and operation. He is well versed in bioprocess equipment design and qualification for large scale fermentor, bioreactor, recovery equipment and chromatography skid for manufacturing.

SHANG CHUNG JU

Executive Director of Process & Facility Engineering

Dr. Shang-Chung Ju has been working in the biotechnology area since 1989 after he earned his Ph.D. degree from National Taiwan University.  His experience has been in the areas of bioprocess development, process transfer, and GMP manufacturing in biopharmaceutical pilot plant facility in DCB (Development Center for Biotechnology), Taiwan. 

As a project manager, he has more than 5 years’ experience in managing process development team and manufacturing team to achieve clients’ goals through the contract development and manufacturing service. 

He has accomplished at least five recombinant proteins form E. coli. and three monoclonal antibodies from CHO or NS0 cells for client’s Phase I/II clinical trial or pre-clinical development purposes. 

He also has experience working with international engineering companies to establish two GMP certified biopharmaceutical facilities for the DCB he served.

CATHY YANG

VICE PRESIDENT & CFO

Ms. Cathy Yang has more than 20 years of experiences in FMCG (Fast Moving Customer Goods) and medical industries. Prior to joining EirGenix, she has been responsible for accounting, finance, HR, administration, and IT departments and also has vast experience in the management and operation of the medical provider channel. Ms. Yang was a General Manager of ERS, which is a JV company between Fresenius and Excelsior, overseeing the management and operations of 100+ kidney dialysis centers in Taiwan. Ms. Yang holds a Master of Science in Accounting from University of New Haven in Connecticut (U.S.).

AE-NING LIN

Executive Director, Analytical Sciences & QC

Dr. Irene, Ae-Ning Lin, a Ph. D. graduate from University of Maryland, College Park, and Post-doc at University of Wisconsin, Madison, has been working in biotechnology field since 1987. She backed to Taiwan and works in the Process Development Division at Development Center for Biotechnology from 1987-2013. She has over thirty years of experience in purification process development, including therapeutic protein, plasmid DNA, bacterial and viral vaccine, enzyme and antibodies. She also has experience for the set-up and operation/validation of biological CGMP pilot plant for the production of phase I/II mammalian derived biologics. Since 2008 Dr. Lin is the Head of Process R & D Department of CGMP pilot plant in Development Center for Biotechnology as well as the co-project director of protein characterization program for the set-up of LC/MS analytical method for protein structure characterization.

After joined EirGenix from Apr. 1st, 2013, Dr. Lin is responsible for the analytical method development and quality control of biologics in terms of characterization, assay development, assay validation, release specification, stability profile and impurity profile monitoring to ensure the quality of therapeutic biologics.